{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-007120","form_type":"8-K","ticker":"AVTR","cik":"0001722482","company_name":"Avantor, Inc.","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.004026+00:00","generated_at":"2026-05-16T03:20:36.975315+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avantor posts $530M net loss in 2025; Q4 organic sales down 4%; Revival program launched","bullets":["Q4 net sales $1.66B, organic decline 4%; net income dropped to $52M from $500M; GAAP EPS $0.08.","FY2025 net loss $530M (vs $712M income); adjusted EBITDA $1,069M; adjusted EPS $0.90.","Revival program includes VWR brand relaunch, manufacturing/supply chain improvements, e-commerce upgrades.","Segment realignment to VWR Distribution & Services and Bioscience & Medtech Products effective Q1 2026.","Adjusted net leverage 3.2x; operating cash flow $624M; free cash flow $496M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-007120","json":"https://secwatch.observer/filing/0001628280-26-007120.json","markdown":"https://secwatch.observer/filing/0001628280-26-007120.md","text":"https://secwatch.observer/filing/0001628280-26-007120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722482/000162828026007120/0001628280-26-007120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722482/000162828026007120/avtr-20260211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:20:36.975315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}